Revamp Medical
Tel Aviv, Israel· Est.
Innovative catheter to boost diuretic response in acute heart failure and cut readmissions.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Innovative catheter to boost diuretic response in acute heart failure and cut readmissions.
CardiovascularAcute Heart Failure
Technology Platform
Doraya is a minimally invasive central venous catheter that temporarily reduces infrarenal IVC flow to lower central venous pressure and improve renal diuretic response in acute heart failure.
Opportunities
Large AHF market with high unmet need for rapid decongestion; potential for reimbursement incentives tied to reduced readmissions.
Risk Factors
Regulatory approval hinges on pivotal trial results; competition from pharmacologic and other device therapies; reimbursement uncertainty.
Competitive Landscape
Few devices target venous hemodynamics in AHF; Doraya’s flow‑reducing catheter differentiates itself by directly enhancing diuretic efficacy without systemic drug escalation.